심장 마커 검사 시장 : 마커 유형별, 제품 유형별, 기술별, 최종 사용자별 시장 예측(2026-2032년)

The Cardiac Marker Testing Market is projected to grow by USD 21.40 billion at a CAGR of 13.67% by 2032.

Executive Introduction to Cardiac Marker Testing

Cardiac marker testing is central to the rapid diagnosis, risk stratification, and monitoring of acute coronary syndrome, heart failure, myocarditis, thromboembolism, and other cardiovascular conditions. High-sensitivity cardiac troponin I and T remain the benchmark biomarkers for myocardial injury, while BNP and NT-proBNP support heart failure evaluation, and markers such as CK-MB, myoglobin, D-dimer, hs-CRP, and emerging multimarker panels provide complementary clinical context.

Demand is supported by the persistent global burden of cardiovascular disease, which the World Health Organization identifies as the leading cause of death worldwide, causing an estimated 17.9 million deaths each year. As emergency departments, clinical laboratories, and point-of-care settings prioritize faster turnaround times and guideline-aligned testing, the cardiac marker testing market is shifting toward high-sensitivity assays, automated platforms, connected diagnostics, and evidence-based clinical decision pathways.

Transformative Shifts in the Cardiac Marker Testing Landscape

The cardiac marker testing landscape is being reshaped by the movement from conventional biomarkers to high-sensitivity and quantitative assays that detect myocardial injury earlier and with greater analytical precision. This transition supports accelerated rule-in and rule-out algorithms for suspected myocardial infarction, reducing unnecessary admissions while improving patient triage in emergency and urgent care environments.

Another transformative shift is the expansion of testing beyond centralized laboratories. Point-of-care cardiac marker analyzers, integrated laboratory information systems, and sample-to-result workflow automation are enabling faster clinical action. At the same time, stricter quality requirements under frameworks such as CLIA, FDA oversight, CE marking, and the EU In Vitro Diagnostic Regulation are pushing assay developers to demonstrate stronger analytical validity, clinical performance, traceability, and post-market surveillance.

Cumulative Impact of Artificial Intelligence on Cardiac Marker Testing

Artificial intelligence is increasingly influencing cardiac marker testing by improving clinical interpretation rather than replacing biomarker science. AI-enabled decision support can combine troponin kinetics, patient history, electrocardiogram findings, age, sex-specific thresholds, renal function, and comorbidities to support more accurate risk stratification for acute coronary syndrome and heart failure.

The cumulative impact is expected to be strongest in workflow optimization, predictive analytics, and quality control. Machine learning models can identify outlier assay performance, reduce diagnostic delays, support population-level surveillance, and enable personalized care pathways. However, adoption depends on transparent validation, bias monitoring, cybersecurity safeguards, clinical governance, and alignment with regulatory expectations for software as a medical device.

Key Regional Insights for Cardiac Marker Testing

North America remains a leading region for cardiac marker testing due to advanced hospital infrastructure, high emergency care utilization, broad access to high-sensitivity troponin assays, and established reimbursement pathways. The United States and Canada continue to support adoption through clinical guideline adherence, laboratory automation, emergency department chest-pain protocols, and active investment in connected diagnostics.

Europe shows strong uptake driven by established cardiology networks, the European Society of Cardiology's support for accelerated high-sensitivity troponin algorithms, and harmonized regulatory scrutiny under the In Vitro Diagnostic Regulation. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, Australia, and ASEAN health systems invest in hospital capacity, emergency medicine, chronic cardiovascular disease management, and local diagnostic manufacturing capabilities.

Latin America, the Middle East, and Africa present uneven but important opportunities shaped by access, affordability, and infrastructure. Brazil and Mexico are strengthening cardiac diagnostic access in urban centers and private hospital networks, GCC countries are investing in advanced hospital systems and preventive cardiology programs, and African markets are prioritizing scalable, affordable testing solutions that can address delayed diagnosis, limited laboratory reach, and growing noncommunicable disease burdens.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are seeing greater demand for affordable point-of-care and hospital-based cardiac marker testing as urbanization, diabetes, hypertension, and improved emergency care capacity increase diagnostic utilization. BRICS countries, led by China, India, Brazil, and supported by large public health systems, are important demand centers because of sizable patient populations, expanding healthcare infrastructure, and policy attention to domestic diagnostic manufacturing and supply resilience.

The European Union is characterized by high regulatory expectations, clinical standardization, and growing adoption of high-sensitivity assays under IVDR compliance. GCC countries are adopting premium diagnostics as part of broader health system modernization and cardiovascular prevention strategies, while G7 nations remain innovation hubs for advanced immunoassay platforms, automation, AI-enabled diagnostics, laboratory accreditation, and reimbursement-backed clinical adoption. NATO countries broadly benefit from mature hospital networks, coordinated procurement practices, and resilient diagnostic supply chains that support continuity of critical cardiac testing.

Key Country Insights for Major Cardiac Marker Testing Markets

The United States leads in advanced cardiac marker testing adoption due to high emergency department volumes, FDA-cleared assays, strong laboratory networks, and integration of high-sensitivity troponin into clinical pathways. Canada emphasizes standardized care and regional laboratory systems, while Mexico and Brazil are expanding access through public and private hospital investments, urban cardiology networks, and broader availability of automated immunoassay platforms.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature adoption of high-sensitivity troponin and natriuretic peptide testing, supported by cardiology guidelines, emergency care protocols, and centralized laboratory quality systems. Russia continues to rely on hospital-based diagnostics with opportunity for modernization in assay platforms, emergency workflows, and wider adoption of standardized cardiac biomarker pathways.

Across Asia-Pacific, China and India represent high-volume growth markets supported by rising cardiovascular disease prevalence, expanding diagnostic infrastructure, and increased investment in tertiary hospitals. Japan and South Korea emphasize technology-driven, high-quality assays, laboratory automation, and quality assurance, while Australia benefits from advanced emergency care systems, strong laboratory accreditation practices, and guideline-based chest-pain assessment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated high-sensitivity troponin, BNP, and NT-proBNP assays that integrate seamlessly with emergency department workflows and laboratory automation platforms. Competitive differentiation will depend on faster turnaround time, strong analytical sensitivity, lower sample volume, interoperability with electronic health records, clear quality-control processes, and evidence supporting improved patient outcomes.

Organizations should also build regional strategies that address affordability, regulatory compliance, and healthcare infrastructure maturity. Partnerships with hospitals, reference laboratories, AI developers, and public health agencies can accelerate adoption, while robust post-market performance monitoring, supply-chain resilience, and clinician education will be essential to sustain trust in cardiac marker testing technologies.

Research Methodology for Cardiac Marker Testing Analysis

This executive summary applies a secondary research-led methodology using verified public health, clinical, regulatory, and industry sources. Key inputs include cardiovascular disease burden data from global health authorities, guideline-based biomarker practices from cardiology organizations, regulatory expectations from major diagnostic markets, and observable adoption trends across hospital laboratories, emergency departments, and point-of-care environments.

Insights are synthesized through market segmentation by biomarker type, testing location, technology platform, end user, region, economic group, and country. The analysis emphasizes data-backed trends, clinical utility, regulatory readiness, workflow impact, and commercial feasibility while avoiding unsupported market-size claims, market share assumptions, or speculative forecasts.

Conclusion: Outlook for Cardiac Marker Testing

Cardiac marker testing is evolving from a laboratory-dependent diagnostic function into a connected, high-sensitivity, and workflow-driven component of cardiovascular care. As cardiovascular disease remains the world's leading cause of mortality, reliable biomarker testing will continue to play a critical role in early diagnosis, risk stratification, treatment monitoring, and hospital resource optimization.

The strongest opportunities will emerge where analytical performance, AI-enabled interpretation, point-of-care access, and regulatory compliance align. Organizations that combine clinical evidence with scalable platforms, strong quality systems, and region-specific commercialization strategies will be best positioned to capture growth in the cardiac marker testing market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Marker Testing Market, by Marker Type

• 7.1. CK-MB
• 7.2. LDH
• 7.3. Myoglobin
• 7.4. Troponin I
  • 7.4.1. Conventional Troponin I
  • 7.4.2. High Sensitivity Troponin I
• 7.5. Troponin T
  • 7.5.1. Conventional Troponin T
  • 7.5.2. High Sensitivity Troponin T

8. Cardiac Marker Testing Market, by Product

• 8.1. Assay Kits
  • 8.1.1. Multiplex Kits
  • 8.1.2. Single Analyte Kits
• 8.2. Instruments
  • 8.2.1. Bench Top Analyzers
  • 8.2.2. Handheld Devices
• 8.3. Reagents
  • 8.3.1. Bulk Reagents
  • 8.3.2. Ready To Use Reagents

9. Cardiac Marker Testing Market, by Technology

• 9.1. Immunoassay
  • 9.1.1. Chemiluminescence Immunoassay
  • 9.1.2. ELISA
• 9.2. Lab Automation
  • 9.2.1. Semi Automated Analyzers
  • 9.2.2. Walkaway Systems
• 9.3. Point Of Care
  • 9.3.1. Biosensor Based Devices
  • 9.3.2. Lateral Flow Immunoassay

10. Cardiac Marker Testing Market, by End User

• 10.1. Clinics
  • 10.1.1. Cardiac Clinics
  • 10.1.2. Outpatient Clinics
• 10.2. Diagnostic Labs
• 10.3. Hospitals
  • 10.3.1. Community Hospitals
  • 10.3.2. Tertiary Hospitals

11. Cardiac Marker Testing Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Cardiac Marker Testing Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Cardiac Marker Testing Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Agilent Technologies, Inc.
• 15.3. Assure Tech (Hangzhou) Co., Ltd.
• 15.4. Atlas Medical GmbH
• 15.5. Becton, Dickinson and Company
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. Bio-Techne Corporation
• 15.8. Biomerieux SA
• 15.9. Boditech Med Inc.
• 15.10. Charles River Laboratories International, Inc.
• 15.11. Cleerly, Inc.
• 15.12. Danaher Corporation
• 15.13. DiaSorin S.p.A.
• 15.14. Eurofins Scientific SE
• 15.15. F. Hoffmann-La Roche AG
• 15.16. HyTest Ltd.
• 15.17. Laboratory Corporation of America Holdings
• 15.18. LightDeck Diagnostics
• 15.19. Merck KGaA
• 15.20. Natera, Inc.
• 15.21. PerkinElmer Inc.
• 15.22. Qiagen N.V.
• 15.23. Quest Diagnostics
• 15.24. QuidelOrtho Corporation
• 15.25. Randox Laboratories Ltd.
• 15.26. Sekbio
• 15.27. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 15.28. Siemens Healthineers AG
• 15.29. Thermo Fisher Scientific Inc.
• 15.30. Tosoh Corporation